

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 38/00, C07K 7/10	A1	(11) International Publication Number: WO 96/23515 (43) International Publication Date: 8 August 1996 (08.08.96)						
<p>(21) International Application Number: PCT/US96/00948</p> <p>(22) International Filing Date: 29 January 1996 (29.01.96)</p> <p>(30) Priority Data:</p> <table border="0"><tr><td>08/381,048</td><td>31 January 1995 (31.01.95)</td><td>US</td></tr><tr><td>08/383,638</td><td>6 February 1995 (06.02.95)</td><td>US</td></tr></table> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/383,638 (CIP) Filed on 6 February 1995 (06.02.95)</p> <p>(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BASINSKI, Margaret, B. [US/US]; 1229 North Hawthorne Lane, Indianapolis, IN 46219 (US). DIMARCHI, Richard, D. [US/US]; 10890 Wilmington Drive, Carmel, IN 46033 (US). HEATH, William, F., Jr. [US/US]; 11214 Tufton Street, Fishers, IN 46038 (US). SCHONER, Brigitte, E. [US/US]; R.R. 2, Box 30 F, Monrovia, IN 46157 (US).</p>		08/381,048	31 January 1995 (31.01.95)	US	08/383,638	6 February 1995 (06.02.95)	US	<p>(74) Agents: CALTRIDER, Steven, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</p> <p>(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
08/381,048	31 January 1995 (31.01.95)	US						
08/383,638	6 February 1995 (06.02.95)	US						
<p>(54) Title: ANTI-OBESITY PROTEINS</p> <p>(57) Abstract</p> <p>The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.</p> <p style="text-align: center;">BEST AVAILABLE COPY</p>								